Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity.

PURPOSE Tobacco smoke is a definite causative agent for lung cancer. It is increasingly being recognized that never-smokers can be afflicted with non-small-cell lung cancer (NSCLC). We aim to assess survival differences between smokers and never-smokers with NSCLC. PATIENTS AND METHODS We analyzed 975 NSCLC patients who presented from January 1999 to December 2002. Clinical characteristics among current-, former- and never-smokers were tested using chi2 or Kruskal-Wallis test. The hazard ratio (HR) for death and its 95% CI were calculated by Cox regression. RESULTS Of 975 patients, 59 had no smoking history and 33 had no quit time recorded. Of 883 patients analyzed, 286 patients (32.4%) were never-smokers. One hundred ninety-six never-smokers (68.5%) were females compared with 12% among current- and 13% among former-smokers (P < .001). There was a significant difference in histologic subtype between never-smokers and smokers: 69.9% with adenocarcinoma versus 39.9% (current-smokers) versus 47.3% (former-smokers); 5.9% with squamous cell carcinoma versus 35.7% (current-smokers) versus 28% (former-smokers; P < .001). Smokers had significantly poorer performance status (P = .002) and higher median age at diagnosis (P < .001) while more never-smokers presented with advanced disease (P = .002). Eight hundred and five patients (82.6%) died by May 30, 2005. The HR for smokers was significantly higher on both univariate and multivariate analysis (HR, 1.297; 95% CI, 1.040 to 1.619). CONCLUSION Never-smokers comprised a high proportion of NSCLC patients in Singapore. Definite epidemiologic differences exist between never-smokers and smokers. Differences in survival outcome further suggest that the biology underlying the pathogenesis and behavior of the disease may be different for never-smokers.

[1]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[2]  S. Leong,et al.  P-123 Molecular profiling of lung cancers: Can it be used as a clinicaltool? , 2005 .

[3]  P. Jänne,et al.  Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Giaccone,et al.  Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Young Tae Kim,et al.  Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Takayuki Kosaka,et al.  Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  William Pao,et al.  Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R Doll,et al.  Mortality from cancer in relation to smoking: 50 years observations on British doctors , 2005, British Journal of Cancer.

[9]  E. A. Graham,et al.  Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma. , 1950, Bulletin of the World Health Organization.

[10]  E. Tan,et al.  The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. , 2004, Chest.

[11]  G. Bepler,et al.  Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. , 2004, Chest.

[12]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[13]  Peter B Bach,et al.  Lung cancer in US women: a contemporary epidemic. , 2004, JAMA.

[14]  P. Kvale,et al.  Smoking and lung cancer survival: the role of comorbidity and treatment. , 2004, Chest.

[15]  F. Speizer,et al.  Prospective study of smoking, antioxidant intake, and lung cancer in middle-aged women (USA) , 2004, Cancer Causes & Control.

[16]  J. Lubin,et al.  Menstrual and Reproductive Factors and Risk of Lung Cancer among Chinese women, Eastern Gansu Province, 1994-1998 , 2007, Journal of epidemiology.

[17]  J. Cerhan,et al.  Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Avrum Spira,et al.  Gene expression in lung adenocarcinomas of smokers and nonsmokers. , 2003, American journal of respiratory cell and molecular biology.

[19]  Jay H Lubin,et al.  Cooking oil fumes and risk of lung cancer in women in rural Gansu, China. , 2002, Lung cancer.

[20]  G. Sheu,et al.  The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. , 2001, Cancer research.

[21]  P. Hainaut,et al.  Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. , 2001, Carcinogenesis.

[22]  M. Usel,et al.  Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. , 2000, The Journal of thoracic and cardiovascular surgery.

[23]  J. Luketich,et al.  Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  B. Zhou,et al.  Meta-analysis of the potential relationship between exposure to environmental tobacco smoke and lung cancer in nonsmoking Chinese women. , 1997, Lung cancer.

[25]  M Paesmans,et al.  Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Alan D. Lopez,et al.  At least one in seven cases of cancer is caused by smoking. Global estimates for 1985 , 1994, International journal of cancer.

[27]  E. Wynder,et al.  Re: Endocrine factors and adenocarcinoma of the lung in women. , 1994, Journal of the National Cancer Institute.

[28]  J. Crowley,et al.  Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  K. Luh,et al.  Epidemiologic characteristics and multiple risk factors of lung cancer in Taiwan. , 1990, Anticancer research.

[30]  J H Ho,et al.  Worldwide epidemiological patterns of lung cancer in nonsmokers. , 1990, International journal of epidemiology.

[31]  N. Lee,et al.  An analysis of some risk factors for lung cancer in Hong Kong , 1985, International journal of cancer.

[32]  H. Shimizu,et al.  Comparison of clinico-epidemiological features of lung cancer patients with and without a history of smoking. , 1984, Japanese journal of clinical oncology.

[33]  K E Warner,et al.  Smoking and lung cancer: an overview. , 1984, Cancer research.

[34]  R. Doll,et al.  Smoking and Carcinoma of the Lung , 1950, Acta - Unio Internationalis Contra Cancrum.